FDA is piloting one-day inspectional assessments — shorter, targeted “safety screening” visits, with facilities selected by artificial intelligence using risk-based criteria. Most early assessments closed as No Action Indicated, but FDA can extend a one-day visit on the spot when significant observations surface. The real message is continuous readiness, because you may not control whether the algorithm picks you.

FDA’s New Inspection Pilot Is Not Business as Usual

FDA is piloting one-day inspectional assessments — shorter, more targeted reviews intended to complement, not replace, standard inspections. Then-Commissioner Marty Makary unveiled the approach at the Food and Drug Law Institute Annual Conference, framing it as a way to focus FDA’s resources where they are most needed. (Makary has since resigned, in May 2026; the pilot has continued under Acting Commissioner Kyle Diamantas.)

For regulated companies, “one-day” can sound less disruptive than a multi-day inspection. That would be the wrong takeaway. A shorter visit can still create serious regulatory consequences — and it carries two features that change the calculus: it is AI-selected, and it can escalate.

Throughout my career, I have provided strategic representation for companies across the food, drug, medical device, and cosmetic industries during FDA inspections and the subsequent enforcement actions that often follow. I frequently guide organizations through the critical period immediately following an inspection, particularly when initial findings escalate into Form FDA 483 observations or formal Warning Letters. What I have seen firsthand from managing these regulatory crises is that the FDA’s tolerance for disorganized records or repeat observations is essentially zero, and such lapses almost always trigger rapid regulatory escalation. When a facility is flagged for an assessment, the difference between a clean closeout and a protracted enforcement battle is the firm’s ability to demonstrate real-time, systemic compliance. I regularly assist clients in developing and submitting comprehensive Corrective and Preventive Action (CAPA) plans within the FDA’s strict 15-business-day response window. By integrating thorough root-cause analyses, robust supplier qualifications, and verifiable interim controls directly into their daily Quality Management Systems, these companies learn to avoid the trap of treating inspection readiness as a one-time event. Whether you are facing a traditional multi-day audit or one of these new AI-driven, one-day screenings, building a culture of continuous readiness is your firm’s best defense.

The Detail Most Coverage Misses: AI Picks the Facilities

The defining feature of this pilot is that FDA uses artificial intelligence to identify facilities for these abridged “safety screening” assessments, drawing on risk-based criteria such as product type, prior inspection outcomes, and operational characteristics. In other words, selection is not purely random or purely complaint-driven — an algorithm is weighing your regulatory profile. As of late April 2026, FDA had completed roughly 46 one-day assessments across multiple inspectorates (human and animal foods, biologics, medical products, and bioresearch monitoring), with the pilot slated to run through fiscal year 2026.AI risk modelselects facilityOne-day screeningtargeted records reviewNo Action Indicatedmost early outcomesEscalationextends beyond one day483 / follow-upfull inspection, lettersA one-day screen can convert into a fuller inspection when significant observations appear. Alt text for WP: flowchart of FDA’s AI-selected one-day assessment process and outcomes.

One-Day vs. Traditional Inspection

What FDA May Review — by Product Category

Scope depends on product type and the reason for the assessment, but companies should expect FDA to focus on high-yield compliance areas: facility registration and product listing, prior inspection history, complaint files and adverse-event records, CAPA and root-cause documentation, batch or lot records, supplier qualification, labeling and claims files, import documentation, recall readiness, and prior FDA correspondence. For device firms, expect emphasis on design controls, complaint handling, MDR reporting, CAPA, and purchasing controls. For drug and biologic companies, on cGMP records, deviations, investigations, stability, and release testing. For food, supplement, and cosmetic companies, on sanitation, ingredient controls, adverse-event records, safety substantiation, and labeling.

Why One Day Still Carries High Stakes

A short assessment can still produce Form FDA 483 observations, records requests, follow-up inspections, warning letters, import holds, recalls, application delays, and heightened scrutiny in future submissions. FDA may also use a one-day screen to decide whether a fuller inspection is warranted or whether to move a firm into a higher-risk category. The exposure is greatest for companies that treat inspection readiness as an event rather than an ongoing function.

How to Prepare

Maintain inspection-ready core records — SOPs, complaint files, CAPA records, supplier records, batch records, labeling files, and adverse-event files that are current, organized, and quickly retrievable. Train front-line personnel on inspection etiquette, escalation, and who is authorized to speak for the company. Review prior FDA correspondence to confirm that past commitments were actually implemented. Run targeted mock assessments that test whether you can respond within a compressed, one-day window. And prepare for the after-visit phase: records requests, written responses, and possible follow-up inspections.

Key Takeaway

FDA’s one-day inspectional assessment pilot signals more agile, data-driven oversight — not relaxed enforcement. An algorithm may decide you warrant a look, and a one-day visit can grow into something larger. Treat readiness as continuous so that, whenever FDA arrives, your quality systems, records, labeling, and corrective actions are current and defensible.

Frequently Asked Questions

How does FDA choose facilities for a one-day assessment?

FDA uses artificial intelligence and risk-based criteria — product type, prior inspection outcomes, and operational characteristics — to select facilities for these screening assessments.

Is a one-day assessment lower risk than a full inspection?

Not necessarily. Many early assessments closed as No Action Indicated, but FDA can extend the visit and escalate to a full inspection when significant observations appear.

Can a one-day assessment result in a Form 483?

Yes. It can produce 483 observations, records requests, follow-up inspections, and other enforcement consequences.

How should we prepare differently for a one-day visit?

Test your ability to produce core records within a single day, not over several. Compressed retrieval is the new readiness benchmark.

This article is attorney advertising and is provided for general informational purposes only. It is not legal advice and does not create an attorney-client relationship. FDA programs and enforcement priorities change frequently; consult qualified FDA regulatory counsel about your specific facility and quality systems.